The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Pharmaceutical and Life Sciences Real World Evidence (RWE) Market by Applications (Early Stage Research, Clinical Development, Regulatory Approval, Pricing / Reimbursement, Post-Approval Studies), Real World Data Sources (Medical Claims, Clinical Trials, Clinical Setting, Patient Powered and Others), Key Therapeutic Areas, and Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    January 2021

  • Pages
    350

  • View Count
    16225

Example Insights

Pharmaceutical-and-Life-Sciences-Real-World-Evidence-Market-Context Pharmaceutical-and-Life-Sciences-Real-World-Evidence-Market-List-Of-Service-providers Pharmaceutical-and-Life-Sciences-Real-World-Evidence-Market-Distribution-by-Year-of-Establishment Pharmaceutical-and-Life-Sciences-Real-World-Evidence-Market-Geographical-Distribution
Pharmaceutical-and-Life-Sciences-Real-World-Evidence-Market-Publication-Analysis Pharmaceutical-and-Life-Sciences-Real-World-Evidence-Market-Stakeholder-Needs-Analysis Pharmaceutical-and-Life-Sciences-Real-World-Evidence-Market-Global-Events-Analysis Pharmaceutical-and-Life-Sciences-Real-World-Evidence-Market-Potential-Acquisition-Targets
Pharmaceutical-and-Life-Sciences-Real-World-Evidence-Market-Use-Cases Pharmaceutical-and-Life-Sciences-Real-World-Evidence-Market-Opportunity    

 

Overview

In recent years, the healthcare industry has witnessed a number of efforts by stakeholders to utilize real world evidence-based insights in official decision making processes; several regulatory authorities / payers have also started acknowledging the potential of real world data and have begun considering insights generated from such data sources for various purposes.

-Head of Market Strategy, a UK-based small-sized real world data provider

Drug discovery and development is a complex and time intensive process that requires a significant amount of resources and capital investments (~USD 2.6 billion). In fact, on an average, the journey from establishment of initial proof-of-concept to product launch, takes around 10-12 years. Moreover, regulatory approval is dependent on the results of randomized clinical trials (RCTs), which are estimated to account for a staggering 40% of the pharmaceutical industry’s budget in the US. It is also well known that clinical research is fraught with various other challenges, including inefficiencies in medical data management and processing, unforeseen delays, risk of failure / study termination and several patient recruitment and retention-related concerns. Further, since such trials are conducted under controlled conditions and involve a fairly homogenous patient population, there are chances that, post commercial launch, approved products fail to perform as expected. In this context, the application of insights from real world data, accrued from past trials, has been demonstrated to have the potential to save up to USD 1 billion per year.  In fact, real world evidence can actually complement results from controlled RCTs, thereby, validating the therapeutic potential of a new chemical / biological entity.

In December 2016, after the 21st Century Cures Act was passed, the United States Food and Drug Administration (USFDA) began considering the application of real world evidence in healthcare decision-making. Ever since, pharmaceutical companies and health economists have developed advanced tools and analytical algorithms to mine pharmaceutical big data, in order to better understand the clinical value of product candidates targeting some of the rarest medical conditions. Presently, big pharmaceutical companies are estimated to spend nearly USD 20 million on an annual basis, on generating real world evidence to support their respective clinical development programs. Over time, insights from real world data have not only influenced product approval-related decisions, but also helped convince insurance provider / payers into offering reimbursement for new drugs / therapies. The growing adoption of artificial intelligence and machine learning in big data analysis, is anticipated to better inform future drug discovery initiatives, thereby, reducing the risk of product failure. The adoption of real world evidence in healthcare decision making is projected to grow substantially as the healthcare industry shifts towards the personalized medicine.

Scope of the Report

The “Pharmaceutical and Life Sciences Real World Evidence (2nd Edition), 2021-2030: Distribution by Type of Applications (Early Stage Research, Clinical Development, Regulatory Approval, Pricing / Reimbursement, Post-Approval Studies), Type of Real World Data Sources (Medical Claims, Clinical Trials, Clinical Setting, Patient Powered and Other Data Sources), Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Infectious Diseases, Metabolic Disorders, Neurological / Psychiatric Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders), and Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)” report features an extensive study of the current market landscape and future potential of the industry players that are engaged in offering real world data / analytics / services to the pharmaceutical and life sciences industries. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the study features:

  • A detailed assessment of the current market landscape of companies that claim to offer real world evidence related solutions based on a number of relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of services offered (real world data, analytics, consulting and services), real world data sources (medical claims, clinical trials, clinical setting, pharmacy, patient-powered and others), and target application areas (early stage research, clinical development, regulatory submission / reimbursement / market access, and post-approval studies).
  • A detailed analysis of completed, ongoing and planned clinical trials conducted in the real world setting based on the multiple parameters, such as trial status, trial registration year, regional distribution, enrolled patient population, type of study, leading industry and non-industry players, emerging focus areas and key therapeutic areas.
  • A detailed publication analysis of more than 950 peer-reviewed, scientific articles that have been published between 2016 and September 2020, highlighting the research focus within the industry. It also highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, types of real world datasets utilized, key disease indications, type of publisher, leading players (in terms of number of publications), region, and key journals (in terms of number of articles published in this domain and impact factor of the journal). 
  • A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of companies that have acquired other firms, offering a means for other industry stakeholders to identify potential acquisition targets. 
  • A social media analysis depicting prevalent and emerging trends, and the popularity of real world evidence solutions, as observed on the social media platform, Twitter. In addition to providing information on yearly trends related to the volume of tweets, the analysis highlights the most frequently talked about real world data sources, target applications, therapeutic areas, active players, and influential authors. The analysis was based on tweets posted on the platform in the last few years.
  • An in-depth analysis of recent events (summits / forums / conferences / annual meetings) that were organized for stakeholders in this domain, highlighting the evolution of discussion topics related to real world evidence. The analysis also provides details on type of event, regional distribution, emerging agendas, popular organizers, active industry and non-industry players, and a schematic mapping of upcoming events.
  • A comparative analysis to understand the needs of different stakeholders (manufacturers, regulators, payers, providers and patients) involved in this domain. 
  • Elaborate profiles of prominent real world evidence service providers. Each company profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective portfolio of technologies / platforms / services, recent developments, and an informed future outlook.
  • An elaborate discussion on data governance and the existing regulatory framework related to real world evidence across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific and rest of the world (Australia, China and Japan).
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall real world evidence market.
  • An insightful discussion on how the recent COVID-19 pandemic likely to impact the real world evidence market, along with key initiatives undertaken by industry players to combat the challenges faced to the pandemic.
  • A list of recent use cases where real world evidence was leveraged by pharmaceutical / medical device companies, highlighting the ways in which companies have utilized such information to support regulatory decisions, advance disease understanding, and develop outcome-based reimbursement model.

One of the key objectives of the report was to estimate the existing market size and future growth potential within the real world evidence market. We have developed informed estimates of the financial evolution of the market, over the period 2021-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] target application areas (early stage research, clinical development, regulatory approval, pricing / reimbursement, and post-approval studies), [B] type of real world data sources used (medical claims, clinical trials, clinical setting, patient-powered and other data sources), [C] therapeutic areas (autoimmune disorders, cardiovascular disorders, infectious diseases, metabolic disorders, neurological / psychiatric disorders, oncological disorders, respiratory disorders and other disorders), and [D] geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our forecast model, we have provided three scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions presented in this study were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

  • Limor BH Epstein (Founder, Data2Life)
  • Anonymous (Vice President, A Big Pharmaceutical Company)
  • Wirth Peter (Vice President, RTI Health Solutions)
  • Douglas Drake (Senior Director, Clinerion) 
  • Fernando Santa (Chief Operating Officer, Adarna Health Data)
  • Jonathan Moshinsky (Chief Strategy Officer, uMotif)
  • Anonymous (Savana)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the real world evidence market in the short-mid term and long term.

Chapter 3 is an introductory chapter that presents a general overview of investment required for developing new medical products, along with information on the limitations associated with randomized clinical trials. Further, it features a detailed discussion on the growing importance of real world evidence and its potential to complement RCTs in healthcare decision-making. It also includes a description of how real world evidence insights is generated from raw, unstructured data, along with details on different sources of data, and the potential applications of this novel approach. Further, the chapter features a discussion on the key growth drivers and roadblocks related to real world evidence, and the novel technologies that are likely to have a notable impact on this industry’s evolution over the coming decade.

Chapter 4 provides a detailed description on the primary elements of data governance and regulatory framework related to real world evidence across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific and rest of the world (Australia, China and Japan).

Chapter 5 provides a detailed assessment of the industry players that claim to offer real world evidence solutions. The chapter presents analysis of these players on the basis of the year of establishment, company size (in terms of number of employees), location of headquarters, type of services offered (real world data, analytics, consulting and services), real world data sources (medical claims, clinical trials, clinical setting, pharmacy, patient-powered and others), and target application areas (early stage research, clinical development, regulatory submission / reimbursement / market access, and post-approval studies).

Chapter 6 features profiles of prominent real world evidence service providers. Each company profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective portfolio of technologies / platforms / services, recent developments and an informed future outlook.

Chapter 7 presents a detailed geographical clinical trial analysis of completed, ongoing and planned studies conducted in the real world setting based on the multiple parameters, such as current trial status, trial registration year, regional distribution, enrolled patient population, type of study, leading industry and non-industry players, emerging focus areas and key therapeutic areas. It also highlights the clinical trials conducted for the novel COVID-19 disease. Further, it presents a benchmarking analysis of the leading industry players (in terms of the number of trials conducted). 

Chapter 8 provides information on certain recent publications that we came across during our research on real world evidence. This chapter features a detailed analysis the key prevalent trends associated with these publications, including information on type of publication, year of publication, study objective, popular keywords, types of real world datasets utilized, key disease indications, type of publisher, leading players (in terms of number of publications), region, and key journals (in terms of number of articles published in this domain and impact factor of the journal) to offer better insights on the emerging trends in this area. 

Chapter 9 provides insights on the popularity of real world evidence on the social media platform, Twitter. The chapter highlights the yearly distribution of tweets posted on the platform in the last few years and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords, real world data sources, target applications, therapeutic areas and players, on the social media platform. It elucidates the most prolific authors and presents a bubble analysis of the most influential authors related to real world evidence on Twitter.

Chapter 10 presents the insights obtained from a detailed analysis of the events organized for stakeholders in this domain. In addition, the chapter provides details on the different agendas of the summits / forums / conferences / workshops that have been conducted over the last few years or are planned to be held in the coming years.  The analyses presented in the chapter are based on different parameters related to the shortlisted global events, such as the date of event, location, type of event and focus area, organizer, and most active stakeholders, and designations / affiliated departments of the participants. 

Chapter 11 presents information on the needs of different stakeholders (manufacturers, regulators, payers, providers and patients) involved in this domain. The chapter qualitatively assesses the real world evidence related needs of each stakeholder group and the relative importance of their expectations within this domain.

Chapter 12 provides a detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms, and offering a means for other industry stakeholders to identify potential acquisition targets.

Chapter 13 provides details on the key parameters and trends that are likely to influence the future of the real world evidence market, under a comprehensive SWOT framework. The chapter also features a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall real world evidence market.

Chapter 14 provides a comprehensive list of notable real world evidence use cases of pharmaceutical / medical device companies in the recent past (since 2016). The chapter highlights how these companies leveraged real world evidence to support their regulatory decisions, advance disease understanding and clinical guidelines, and assist outcome-based reimbursement decisions. In addition, the chapter presents an insightful opportunity analysis, estimating the existing market size and potential growth opportunities of real world evidence across different applications (early stage research, clinical development, regulatory approval, pricing / reimbursement, and post-approval studies). Based on multiple parameters, such as number of pre- or post-approval studies conducted annually, investment associated with these studies, and the likely cost and time saving opportunities, we have provided an informed estimate on the likely evolution of the market over the period 2021-2030. In addition, the report provides detailed market segmentation on the basis of type of real world data sources (medical claims, clinical trials, clinical setting, patient-powered and other data sources), therapeutic area (autoimmune disorders, cardiovascular disorders, infectious diseases, metabolic disorders, neurological / psychiatric disorders, oncological disorders, respiratory disorders and other disorders), and the geographical distribution of the market (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). 

Chapter 15 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the real world evidence domain. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their offerings and the associated commercial potential.

Chapter 16 highlights the impact of COVID-19 outbreak on the real world evidence market. In addition, it features a brief discussion on the key initiatives undertaken by players.

Chapter 17 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario.

Chapter 18 is a collection of transcripts of interviews conducted with various key stakeholders during the course of this study. We have presented the details of our discussions with Limor BH Epstein (Founder, Data2Life), Anonymous (Vice President, Big Pharmaceutical Company), Wirth Peter (Vice President, RTI Health Solutions), Douglas Drake (Senior Director, Clinerion), Fernando Santa (Chief Operating Officer, Adarna Health Data), Jonathan Moshinsky (Chief Strategy Officer, uMotif), and Anonymous (Savana).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Need for Real World Evidence
3.2.1. Growing Concerns Related to Chronic Disorders
3.2.2. High Investments in Drug Development
3.2.3. Role of Randomized Clinical Trials
3.2.4. Shift from Volume- to Value-based Care

3.3. Overview of Real World Evidence
3.3.1. Sources of Real World Data
3.3.1.1. Medical Claims Data
3.3.1.2. Clinical Trial Data
3.3.1.3. Patient-powered Data
3.3.1.4. Pharmacy Data
3.3.1.5. Other Real World Data Sources

3.3.2. Comparison of Randomized Clinical Trials and Real World Evidence
3.3.3. Advantages and Limitations of Real World Evidence
3.3.4. Potential Applications of Real World Evidence
3.3.5. Growth Drivers and Challenges

3.4. Role of Advanced Techniques in Real World Data Management
3.5. Future Perspectives

4. DATA GOVERNANCE AND REGULATORY FRAMEWORK FOR REAL WORLD EVIDENCE
4.1. Chapter Overview
4.2. Primary Elements of Data Governance for Real World Evidence
4.3. Importance of Regulatory Framework for Real World Evidence

4.4. Data Governance and Regulatory Framework in North America
4.4.1. The US Scenario
4.4.1.1. Data Governance
4.4.1.2. Regulatory Framework

4.4.2. The Canadian Scenario
4.4.2.1. Data Governance
4.4.2.2. Regulatory Framework

4.5. Data Governance and Regulatory Framework in Europe
4.5.1. The UK Scenario
4.5.1.1. Data Governance
4.5.1.2. Regulatory Framework

4.5.2. The German Scenario
4.5.2.1. Data Governance
4.5.2.2. Regulatory Framework

4.5.3. The French Scenario
4.5.3.1. Data Governance
4.5.3.2. Regulatory Framework

4.5.4. The Spanish Scenario
4.5.5. The Italian Scenario

4.6. Data Governance and Regulatory Framework in Asia-Pacific and Rest of the World
4.6.1. The Australian Scenario
4.6.2. The Chinese Scenario
4.6.3. The Japanese Scenario

5. CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Real World Evidence Solution Providers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Business Model
5.2.5. Analysis by Type of Services Offered
5.2.6. Analysis by Real World Data Source
5.2.7. Analysis by Key Applications of Real World Evidence
5.2.8. Analysis by Key Therapeutic Areas

6. COMPANY PROFILES 
6.1. Chapter Overview
6.2. Clinerion
6.2.1. Company Overview
6.2.2. Technology Overview
6.2.3. Recent Developments and Future Outlook

6.3. Clinigen Group
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook

6.4. Cognizant Analytics
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook

6.5. Evidera
6.5.1. Company Overview
6.5.2. Technology Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. HealthCore
6.6.1. Company Overview
6.6.2. Recent Developments and Future Outlook

6.7. IBM
6.7.1. Company Overview
6.7.2. Technology Portfolio
6.7.3. Recent Developments and Future Outlook

6.8. ICON
6.8.1. Company Overview
6.8.2. Technology Portfolio
6.8.3. Recent Developments and Future Outlook

6.9. IQVIA
6.9.1. Company Overview
6.9.2. Technology Portfolio
6.9.3. Recent Developments and Future Outlook

6.10. Medpace
6.10.1. Company Overview
6.10.2. Technology Overview
6.10.3. Recent Developments and Future Outlook

6.11. NorthWest EHealth
6.11.1. Company Overview
6.11.2. Technology Overview
6.11.3. Recent Developments and Future Outlook

6.12. Optum Insight
6.12.1. Company Overview
6.12.2. Recent Developments and Future Outlook

6.13. Oracle
6.13.1. Company Overview
6.13.2. Technology Portfolio
6.13.3. Recent Developments and Future Outlook
6.14. PAREXEL
6.14.1. Company Overview
6.14.2. Technology Overview
6.14.3. Recent Developments and Future Outlook

6.15. Perkin Elmer
6.15.1. Company Overview
6.15.2. Recent Developments and Future Outlook

6.16. SAS
6.16.1. Company Overview
6.16.2. Technology Portfolio
6.16.3. Recent Developments and Future Outlook

6.17. Syneos Health
6.17.1. Company Overview
6.17.2. Recent Developments and Future Outlook

6.18. TriNetX
6.18.1. Company Overview
6.18.2. Technology Overview
6.18.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS 
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Real World Evidence: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Recruitment Status
7.3.3. Analysis by Type of Study
7.3.4. Analysis by Type of Sponsor / Collaborator
7.3.5. Most Active Players: Analysis by Number of Trials
7.3.6. Geographical Analysis by Number of Clinical Trials
7.3.7. Geographical Analysis by Enrolled Patient Population
7.3.8. Emerging Focus Areas
7.3.9. Analysis by Key Therapeutic Areas
7.3.10. Grid Representation: Analysis by Key Therapeutic Areas, Number of Trials and Leading Players
7.3.11. Benchmark Analysis of Key Industry Players

8. PUBLICATION ANALYSIS 
8.1. Chapter Overview
8.2. Scope and Methodology

8.3. Real World Evidence: Recent Publications
8.3.1. Analysis by Year of Publication
8.3.2. Analysis by Emerging Focus Areas
8.3.3. Analysis by Real World Data Sources
8.3.4. Analysis by Key Indications Examined
8.3.5. Leading Players: Analysis by Number of Publications
8.3.6. Geographical Analysis by Number of Publications

8.3.7. Analysis by Key Research Journals
8.3.7.1. Key Journals: Analysis by Number of Publications
8.3.7.2. Key Journals: Analysis by Journal Impact Factor

8.3.8. Most Popular Authors: Analysis by Number of Publications

9. EMERGING TRENDS ON SOCIAL MEDIA
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Real World Evidence: Trends on Twitter
9.3.1. Historical Trends in Volume of Tweets
9.3.2. Popular Keywords
9.3.3. Popular Real World Data Sources
9.3.4. Popular Applications of Real World Evidence
9.3.5. Popular Therapeutic Areas
9.3.6. Popular Stakeholders
9.3.7. Most Prolific Contributors
9.3.8. Most Influential Contributors

10. GLOBAL EVENTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Real World Evidence: Global Events Analysis
10.3.1. Analysis by Year of Occurrence
10.3.2. Analysis by Event Platform
10.3.3. Analysis by Type of Event 
10.3.4. Analysis by Geography 
10.3.5. Evolutionary Trends in Key Focus Area / Event Agenda
10.3.6. Most Active Event Organizers
10.3.7. Most Active Participants: Analysis by Number of Events
10.3.8. Analysis by Seniority Level of Participants
10.3.9. Geographical Mapping of Upcoming Events

11. STAKEHOLDER NEEDS ANALYSIS
11.1. Chapter Overview
11.2. Real World Evidence: Approaches for Data Generation
11.3. Real World Evidence: Needs of Different Stakeholders
11.4. Real World Evidence: Comparison of Needs of Various Stakeholders
11.4.1. Needs of Healthcare Providers
11.4.2. Needs of Manufacturers
11.4.3. Needs of Payers
11.4.4. Needs of Patients
11.4.5. Needs of Regulators

12. KEY ACQUISITION TARGETS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Scoring Criteria and Key Assumptions
12.4. Potential Strategic Acquisition Targets in North America
12.5. Potential Strategic Acquisition Targets in Europe
12.6. Potential Strategic Acquisition Targets in Asia-Pacific and Rest of the World
12.7. Concluding Remark

13. SWOT ANALYSIS
13.1. Chapter Overview
13.2. Real World Evidence: SWOT Analysis
13.2.1. Comparison of SWOT Factors

14. COST SAVING AND MARKET OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Real World Evidence Use Cases
14.3. Real World Evidence Market Opportunity Assessment
14.3.1 Methodology and Key Assumptions

14.4. Overall Real World Evidence Market Opportunity in Drug Development, 2021-2030
14.4.1. Real World Evidence Market Opportunity across Different Type of Sources
14.4.1.1. Real World Evidence Market Opportunity from Medical Claims Data, 2021-2030
14.4.1.2. Real World Evidence Market Opportunity from Clinical Trials Data, 2021-2030
14.4.1.3. Real World Evidence Market Opportunity from Clinical Settings Data, 2021-2030
14.4.1.4. Real World Evidence Market Opportunity from Patient-Powered Data, 2021-2030
14.4.1.5. Real World Evidence Market Opportunity from Other Types of Data, 2021-2030

14.4.2. Overall Real World Evidence Market Opportunity across Different Therapeutic
14.4.2.1. Real World Evidence Market Opportunity for Autoimmune Disorders, 2021-2030
14.4.2.2. Real World Evidence Market Opportunity for Cardiovascular Disorders, 2021-2030
14.4.2.3. Real World Evidence Market Opportunity for Infectious Diseases, 2021-2030
14.4.2.4. Real World Evidence Market Opportunity for Metabolic Disorders, 2021-2030
14.4.2.5. Real World Evidence Market Opportunity for Neurological / Psychiatric Disorders, 2021-2030
14.4.2.6. Real World Evidence Market Opportunity for Oncological Disorders, 2021-2030
14.4.2.7. Real World Evidence Market Opportunity for Respiratory Disorders, 2021-2030
14.4.2.8. Real World Evidence Market Opportunity for Other Disorders, 2021-2030

14.4.3. Overall Real World Evidence Market Opportunity across Different Areas of
14.4.3.1. Real World Evidence Market Opportunity in Early Stage Research, 2021-2030
14.4.3.2. Real World Evidence Market Opportunity in Clinical Development, 2021-2030
14.4.3.3. Real World Evidence Market Opportunity in Regulatory Approval, 2021-2030
14.4.3.4. Real World Evidence Market Opportunity in Pricing / Reimbursement, 2021-2030
14.4.3.5. Real World Evidence Market Opportunity in Post-Approval Studies, 2021-2030

14.4.4. Overall Real World Evidence Market Opportunity across Different Geographies
14.4.4.1. Real World Evidence Market Opportunity in North America, 2021-2030
14.4.4.2. Real World Evidence Market Opportunity in Europe, 2021-2030
14.4.4.3. Real World Evidence Market Opportunity in Asia-Pacific, 2021-2030
14.4.4.4. Real World Evidence Market Opportunity in Latin America, 2021-2030
14.4.4.5. Real World Evidence Market Opportunity in Middle East and North Africa (MENA), 2021-2030
14.4.4.6. Real World Evidence Market Opportunity in Rest of the World (RoW), 2021-2030

14.5. Concluding Remarks

15. SURVEY INSIGHTS
15.1. Chapter Overview
15.2. Analysis by Designation of Respondents
15.3. Analysis by Type of Services Offered
15.4. Analysis by Real World Data Sources
15.5. Analysis by Applications of Real World Evidence
15.6. Analysis by Key Challenges in Generating Real World Evidence
15.7. Analysis by Extent of Outsourcing
15.8. Current Annual Budget for Real World Evidence

16. IMPACT OF COVID-19 ON REAL WORLD EVIDENCE MARKET
16.1. Chapter Overview
16.2. Current Options and Recuperative Initiatives of Key Players
16.3. Impact on Real World Evidence Market Opportunity

17. CONCLUSION

18. INTERVIEW TRANSCRIPTS
18.1. Chapter Overview
18.2. Limor BH Epstein, Founder, Data2Life
18.3. Anonymous, Vice President, Big Pharmaceutical Company 
18.4. Wirth Peter, Vice President, RTI Health Solutions
18.5. Douglas Drake (Senior Director, Clinerion)
18.6. Fernando Santa (Chief Operating Officer, Adarna Health Data)
18.7. Jonathan Moshinsky, Head of Market Strategy, uMotif
18.8. Anonymous, Savana

19. APPENDIX 1: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Role of Real World Data in Shaping Healthcare Decision-making
Figure 3.2 Common Types of Chronic Disorders and their Rapidly Increasing Prevalence
Figure 3.3 Drug Development Costs: Historical Trend (USD Million)
Figure 3.4 Limitations of Randomized Clinical Trials
Figure 3.5 Traditional versus Outcome-based Development Model
Figure 3.6 Process of Generating Evidence from Real World Data
Figure 3.7 Type of Real World Data Sources
Figure 3.8 Different Constituents of Real World Data Sources
Figure 3.9 Randomized Clinical Trials versus Real World Evidence
Figure 3.10 Potential Applications of Real World Evidence
Figure 3.11 Potential Applications of Real World Evidence across Different Stages of Drug Development and Commercialization: A Summary
Figure 3.12 Growth Drivers and Potential Roadblocks of Real World Evidence
Figure 4.1 Real World Evidence: Primary Elements of Data Governance
Figure 4.2 Real World Evidence: Ideal Regulatory Framework
Figure 4.3 Emergence of Real World Evidence in China
Figure 5.1 Real World Evidence Solution Providers: Distribution by Year of Establishment
Figure 5.2 Real World Evidence Solution Providers: Distribution by Company Size
Figure 5.3 Real World Evidence Solution Providers: Distribution by Location of Headquarters
Figure 5.4 Real World Evidence Solution Providers: Distribution by Type of Business Model
Figure 5.5 Real World Evidence Solution Providers: Distribution by Type of Services Offered
Figure 5.6 Real World Evidence Solution Providers: Distribution by Real World Data Source
Figure 5.7 Real World Evidence Solution Providers: Distribution by Key Applications of Real World Evidence
Figure 5.8 Real World Evidence Solution Providers, Grid Analysis: Distribution by Company Size, Type of Offering and Applications of Real World Evidence
Figure 5.9 Real World Evidence Solution Providers: Distribution by Key Therapeutic Areas
Figure 7.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 7.3 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 7.5 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.6 Clinical Trial Analysis: Dot Plot of Number of Trials and Enrolled Patient Population
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.8 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status
Figure 7.9 Clinical Trial Analysis: Distribution by Type of Study
Figure 7.10 Clinical Trial Analysis: Distribution by Trial Registration Year and Type of Study
Figure 7.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.12 Clinical Trial Analysis: Most Active Industry Players
Figure 7.13 Clinical Trial Analysis: Most Active Non-Industry Players
Figure 7.14 Clinical Trial Analysis: Evolutionary Trends in Key Focus Areas
Figure 7.15 Clinical Trial Analysis: Distribution by Key Therapeutic Areas
Figure 7.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Key Therapeutic Areas
Figure 7.17 Clinical Trial Analysis: Leading Indications
Figure 7.18 Grid Representation: Distribution by Key Therapeutic Areas, Number of Trials and Leading Players
Figure 7.19 Clinical Trial Analysis: Year Wise Trend of Trials Conducted by Leading Industry Players, 2013-2020
Figure 7.20 Clinical Trial Analysis: Benchmarking of Leading Industry Players by Number of Trials across Key Therapeutic Areas
Figure 8.1 Publication Analysis: Distribution by Type of Publication
Figure 8.2 Publication Analysis: Cumulative Year-wise Trend, 2016-Q3 2020
Figure 8.3 Publication Analysis: Distribution by Key Focus Areas
Figure 8.4 Publication Analysis: Word Cloud of Study Titles
Figure 8.5 Publication Analysis: Distribution by Real World Data Sources
Figure 8.6 Publication Analysis: Key Indications (in Terms of Number of Published Studies)
Figure 8.7 Publication Analysis: Distribution by Type of Sponsor
Figure 8.8 Publication Analysis: Most Active Industry Players (in Terms of Number of Published Studies)
Figure 8.9 Publication Analysis: Geographical Distribution of Authors
Figure 8.10 Publication Analysis: Key Journals (in Terms of Number of Published Studies)
Figure 8.11 Publication Analysis: Key Journals (in Terms of Impact Factor)
Figure 8.12 Publication Analysis: Most Popular Authors
Figure 9.1 Trends on Social Media: Historical Activities on Twitter
Figure 9.2 Trends on Social Media: Cumulative Year-wise Distribution (in terms of Volume of Tweets)
Figure 9.3 Trends on Social Media: Most Popular Keywords
Figure 9.4 Trends on Social Media: Most Popular Real World Data Sources
Figure 9.5 Trends on Social Media: Most Popular Applications of Real World Evidence
Figure 9.6 Trends on Social Media: Most Popular Therapeutic Areas
Figure 9.7 Trends on Social Media: Most Popular Stakeholders
Figure 9.8 Trends on Social Media: Most Prolific Contributors
Figure 9.9 Trends on Social Media: Most Influential Contributors
Figure 10.1 Global Events Analysis: Cumulative Quarter-wise Trend, H1 2017-2020
Figure 10.2 Global Events Analysis: Distribution by Event Platform
Figure 10.3 Global Events Analysis: Distribution by Event Location
Figure 10.4 Global Events Analysis: Distribution by Type of Event
Figure 10.5 Global Events Analysis: Evolutionary Trend in Key Focus Areas
Figure 10.6 Global Events Analysis: Historical Trend of Event Agendas, 2017-2020
Figure 10.7 Global Events Analysis: Most Active Event Organizers
Figure 10.8 Global Events Analysis: Most Active Industry Players (in terms of Event Participation)
Figure 10.9 Global Events Analysis: Most Active Non-Industry Players (in terms of Event Participation)
Figure 10.10 Global Events Analysis: Distribution by Designations of Event Participants
Figure 10.11 Global Events Analysis: Distribution by Affiliated Departments of Event Participants
Figure 10.12 Global Events Analysis: Geographical Mapping of Upcoming Events
Figure 11.1 Comparison of Historical and Optimal Approach of Real World Evidence Generation
Figure 11.2 Stakeholder Needs Analysis: Comparison of Stakeholders
Figure 11.3 Stakeholder Needs Analysis: Distribution of Stakeholders based on Real World Data Usability
Figure 11.4 Stakeholder Needs Analysis: Comparison of Needs of Stakeholders
Figure 11.5 Stakeholder Needs Analysis: Distribution of Needs based on Current and Future Relevance
Figure 11.6 Stakeholder Needs Analysis: Needs of Healthcare Providers based on Current and Future Relevance
Figure 11.7 Stakeholder Needs Analysis: Needs of Manufacturers based on Current and Future Relevance
Figure 11.8 Stakeholder Needs Analysis: Needs of Payers based on Current and Future Relevance
Figure 11.9 Stakeholder Needs Analysis: Needs of Patients based on Current and Future Relevance
Figure 11.10 Stakeholder Needs Analysis: Needs of Regulators based on Current and Future Relevance
Figure 12.1 Key Acquisition Targets: Potential Targets in North America
Figure 12.2 Key Acquisition Targets: Potential Targets in Europe
Figure 12.3 Key Acquisition Targets: Potential Targets in Asia-Pacific and Rest of the World
Figure 12.4 Likely Acquisition Targets: Geographical Distribution
Figure 13.1 Real World Evidence: SWOT Analysis
Figure 13.2 Comparison of SWOT Factors
Figure 14.1 Global Real World Evidence Market Opportunity, 2021-2030 (USD Million)
Figure 14.2 Real World Evidence Market Opportunity, 2021-2030: Distribution by Type of Real World Data Source
Figure 14.3 Real World Evidence Market Opportunity from Medical Claims Data, 2021-2030 (USD Million)
Figure 14.4 Real World Evidence Market Opportunity from Clinical Trials Data, 2021-2030 (USD Million)
Figure 14.5 Real World Evidence Market Opportunity from Clinical Settings Data, 2021-2030 (USD Million)
Figure 14.6 Real World Evidence Market Opportunity from Patient-Powered Data, 2021-2030 (USD Million)
Figure 14.7 Real World Evidence Market Opportunity from Other Types of Data, 2021-2030 (USD Million)
Figure 14.8 Real World Evidence Market Opportunity, 2021-2030: Distribution by Therapeutic Areas
Figure 14.9 Real World Evidence Market Opportunity for Autoimmune Disorders, 2021-2030
Figure 14.10 Real World Evidence Market Opportunity for Cardiovascular Disorders, 2021-2030 (USD Million)
Figure 14.11 Real World Evidence Market Opportunity for Infectious Diseases, 2021-2030 (USD Million)
Figure 14.12 Real World Evidence Market Opportunity for Metabolic Disorders, 2021-2030 (USD Million)
Figure 14.13 Real World Evidence Market Opportunity for Neurological / Psychiatric Disorders, 2021-2030 (USD Million)
Figure 14.14 Real World Evidence Market Opportunity for Oncological Disorders, 2021-2030 (USD Million)
Figure 14.15 Real World Evidence Market Opportunity for Respiratory Disorders, 2021-2030 (USD Million)
Figure 14.16 Real World Evidence Market Opportunity for Other Types of Disorders, 2021-2030 (USD Million)
Figure 14.17 Real World Evidence Market Opportunity, 2021-2030: Distribution by Key Applications
Figure 14.18 Real World Evidence Market Opportunity in Early Stage Research, 2021-2030 (USD Million)
Figure 14.19 Real World Evidence Market Opportunity in Clinical Development, 2021-2030 (USD Million)
Figure 14.20 Real World Evidence Market Opportunity in Regulatory Approval, 2021-2030 (USD Million)
Figure 14.21 Real World Evidence Market Opportunity in Pricing / Reimbursement, 2021-2030 (USD Million)
Figure 14.22 Real World Evidence Market Opportunity in Post-Approval Studies, 2021-2030 (USD Million)
Figure 14.23 Real World Evidence Market Opportunity, 2021-2030: Distribution by Geography
Figure 14.24 Real World Evidence Market Opportunity in North America, 2021-2030 (USD Million)
Figure 14.25 Real World Evidence Market Opportunity in Europe, 2021-2030 (USD Million)
Figure 14.26 Real World Evidence Market Opportunity in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.27 Real World Evidence Market Opportunity in Latin America, 2021-2030 (USD Million)
Figure 14.28 Real World Evidence Market Opportunity in MENA, 2021-2030 (USD Million)
Figure 14.29 Real World Evidence Market Opportunity in Rest of the World, 2021-2030 (USD Million)
Figure 14.30 Overall Real World Evidence Market Opportunity, Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
Figure 15.1 Survey Analysis: Distribution by Type of Company
Figure 15.2 Survey Analysis: Distribution by Location of Company
Figure 15.3 Survey Analysis: Distribution by Designation and Seniority Level of Respondents
Figure 15.4 Survey Analysis: Distribution by Types of Services Offered
Figure 15.5 Survey Analysis: Distribution by Real World Data Sources
Figure 15.6 Survey Analysis: Distribution by Applications of Real World Evidence Generation
Figure 15.7 Survey Analysis: Distribution by Key Challenges
Figure 15.8 Survey Analysis: Distribution by Extent of Outsourcing
Figure 15.9 Survey Analysis: Distribution by Average Budget Allocated by Big Pharmaceutical Companies
Figure 16.1 Real World Evidence Market, 2021-2030: COVID-19 Impact Scenario
Figure 17.1 Concluding Remarks: Current Market Landscape
Figure 17.2 Concluding Remarks: Clinical Trial Analysis
Figure 17.3 Concluding Remarks: Publication Analysis
Figure 17.4 Concluding Remarks: Global Events Analysis
Figure 17.5 Concluding Remarks: Key Acquisition Targets
Figure 17.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Primary Elements of Different Sources of Real World Data
Table 3.2 Real World Evidence: Opportunities in Pharmaceutical and Medical Device Industries
Table 3.3 Randomized Clinical Trials versus Real World Evidence
Table 5.1 Real World Evidence Solution Providers: List of Industry Players
Table 5.2 Real World Evidence Solution Providers: Information on Business Model and Service Offerings
Table 5.3 Real World Evidence Solution Providers: Information on Real World Data Sources
Table 5.4 Real World Evidence Solution Providers: Information on Applications
Table 6.1 List of Companies Profiled
Table 6.2 Clinerion: Company Snapshot
Table 6.3 Clinerion: Recent Developments and Future Outlook
Table 6.4 Clinigen Group: Company Snapshot
Table 6.5 Clinigen Group: Recent Developments and Future Outlook
Table 6.6 Cognizant Analytics: Company Snapshot
Table 6.7 Cognizant Analytics: Recent Developments and Future Outlook
Table 6.8 Evidera: Company Snapshot
Table 6.9 Evidera: Recent Developments and Future Outlook
Table 6.10 HealthCore: Company Snapshot
Table 6.11 HealthCore: Recent Developments and Future Outlook
Table 6.12 IBM: Company Snapshot
Table 6.13 IBM: Recent Developments and Future Outlook
Table 6.14 ICON: Company Snapshot
Table 6.15 ICON: Recent Developments and Future Outlook
Table 6.16 IQVIA: Company Snapshot
Table 6.17 IQVIA: Recent Developments and Future Outlook
Table 6.18 Medpace: Company Snapshot
Table 6.19 Medpace: Recent Developments and Future Outlook
Table 6.20 NorthWest EHealth: Company Snapshot
Table 6.21 NorthWest EHealth: Recent Developments and Future Outlook
Table 6.22 Optum Insight: Company Snapshot
Table 6.23 Optum Insight: Recent Developments and Future Outlook
Table 6.24 Oracle: Company Snapshot
Table 6.25 Oracle: Recent Developments and Future Outlook
Table 6.26 PAREXEL: Company Snapshot
Table 6.27 PAREXEL: Recent Developments and Future Outlook
Table 6.28 Perkin Elmer: Company Snapshot
Table 6.29 Perkin Elmer: Recent Developments and Future Outlook
Table 6.30 SAS: Company Snapshot
Table 6.31 SAS: Recent Developments and Future Outlook
Table 6.32 Syneos Health: Company Snapshot
Table 6.33 Syneos Health: Recent Developments and Future Outlook
Table 6.34 TriNetX: Company Snapshot
Table 6.35 TriNetX: Recent Developments and Future Outlook
Table 7.1 List of Leading Clinical Trials by Enrolled Patient Population
Table 7.2 List of Clinical Trials for COVID-19
Table 10.1 List of Global Events Related to Real World Evidence, 2017-2020
Table 14.1 List of Use Cases Related to Real World Evidence, 2016-2020
Table 15.1 Survey Analysis: Overview of Respondents
Table 15.2 Survey Analysis: Designation and Seniority Level of Respondents
Table 15.3 Survey Analysis: Types of Services Offered
Table 15.4 Survey Analysis: Real World Data Sources
Table 15.5 Survey Analysis: Applications of Real World Evidence
Table 15.6 Survey Analysis: Key Challenges
Table 15.7 Survey Analysis: Extent of Outsourcing
Table 15.8 Survey Analysis: Average Budget Allocated by Big Pharmaceutical Companies
Table 16.1 FDA Issued COVID-19 Projects Related to Real World Evidence
Table 18.1 Data2Life: Company Snapshot
Table 18.2 Adarna Health Data: Company Snapshot
Table 18.3 RTI Health Solutions: Company Snapshot
Table 18.4 Clinerion: Company Snapshot
Table 18.5 uMotif: Company Snapshot
Table 18.6 Savana: Company Snapshot
Table 19.1 Drug Development Costs: Historical Trend (USD Million)
Table 19.2 Real World Evidence Solution Providers: Distribution by Year of Establishment
Table 19.3 Real World Evidence Solution Providers: Distribution by Company Size
Table 19.4 Real World Evidence Solution Providers: Distribution by Location of Headquarters
Table 19.5 Real World Evidence Solution Providers: Distribution by Type of Business Model
Table 19.6 Real World Evidence Solution Providers: Distribution by Type of Services Offered
Table 19.7 Real World Evidence Solution Providers: Distribution by Real World Data Sources
Table 19.8 Real World Evidence Solution Providers: Distribution by Key Applications
Table 19.9 Tree Map Representation: Distribution by Company Size and Applications of Real World Evidence
Table 19.10 Real World Evidence Solution Providers: Distribution by Key Therapeutic Areas
Table 19.11 Clinical Trial Analysis: Distribution by Trial Status
Table 19.12 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 19.13 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 19.14 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 19.15 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 19.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 19.17 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status
Table 19.18 Clinical Trial Analysis: Distribution by Type of Study
Table 19.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Type of Study
Table 19.20 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.21 Clinical Trial Analysis: Most Active Industry Players
Table 19.22 Clinical Trial Analysis: Most Active Non-Industry Players
Table 19.23 Clinical Trial Analysis: Distribution by Key Therapeutic Areas
Table 19.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Key Therapeutic Areas
Table 19.25 Clinical Trial Analysis: Leading Indications
Table 19.26 Clinical Trial Analysis: Year Wise Trend of Trials Conducted by Leading Industry Players, 2013-2020
Table 19.27 Clinical Trial Analysis: Benchmarking of Leading Industry Players by Number of Trials Across Key Therapeutic Areas
Table 19.28 Publication Analysis: Distribution by Type of Publication
Table 19.29 Publication Analysis: Cumulative Year-wise Trend, (2016-Q3 2020)
Table 19.30 Publication Analysis: Distribution by Key Focus Areas
Table 19.31 Publication Analysis: Distribution by Real World Data Sources
Table 19.32 Publication Analysis: Key Indications in Terms of Number of Published Studies
Table 19.33 Publication Analysis: Distribution by Type of Sponsors
Table 19.34 Publication Analysis: Most Active Industry Players in Terms of Number of Published Studies
Table 19.35 Publication Analysis: Geographical Distribution of Authors
Table 19.36 Publication Analysis: Key Journals (in Terms of Number of Published Studies)
Table 19.37 Publication Analysis: Key Journals by Impact Factor (In Terms of Impact Factor)
Table 19.38 Publication Analysis: Most Popular Authors
Table 19.39 Trends on Social Media: Cumulative Year-wise Analysis by Volume of Tweets, 2013-H1 2018
Table 19.40 Global Events Analysis: Cumulative Half Year-wise Trend, H1 2017-2021
Table 19.41 Global Events Analysis: Distribution by Event Platform
Table 19.42 Global Events Analysis: Distribution by Event Location
Table 19.43 Global Events Analysis: Distribution by Type of Event
Table 19.44 Global Events Analysis: Most Active Event Organizers
Table 19.45 Global Events Analysis: Most Active Industry Players (in terms of Event Participation
Table 19.46 Global Events Analysis: Most Active Non-Industry Players (in terms of Event Participation
Table 19.47 Global Events Analysis: Distribution by Designations of Event Participants
Table 19.48 Global Events Analysis: Distribution by Affiliated Departments of Event Participants
Table 19.49 Global Real World Evidence Market Opportunity, 2021-2030 (USD Million)
Table 19.50 Real World Evidence Market Opportunity, 2021-2030: Distribution by Different Type of Real World Data Sources
Table 19.51 Real World Evidence Market Opportunity from Medical Claims Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.52 Real World Evidence Market Opportunity from Clinical Trials Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.53 Real World Evidence Market Opportunity from Clinical Settings Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.54 Real World Evidence Market Opportunity from Patient-Powered Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.55 Real World Evidence Market Opportunity from Other Types of Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.56 Real World Evidence Market Opportunity, 2021-2030: Distribution by Therapeutic Areas
Table 19.57 Real World Evidence Market Opportunity for Autoimmune Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.58 Real World Evidence Market Opportunity for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.59 Real World Evidence Market Opportunity for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.60 Real World Evidence Market Opportunity for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.61 Real World Evidence Market Opportunity for Neurological / Psychiatric Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.62 Real World Evidence Market Opportunity for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.63 Real World Evidence Market Opportunity for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.64 Real World Evidence Market Opportunity for Other Types of Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.65 Real World Evidence Market Opportunity, 2021-2030: Distribution by Key Applications
Table 19.66 Real World Evidence Market Opportunity in Early Stage Research, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.67 Real World Evidence Market Opportunity in Clinical Development, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.68 Real World Evidence Market Opportunity in Regulatory Approval, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.69 Real World Evidence Market Opportunity in Pricing / Reimbursement, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.70 Real World Evidence Market Opportunity in Post-Approval Studies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.71 Real World Evidence Market Opportunity, 2021-2030: Distribution by Geography
Table 19.72 Real World Evidence Market Opportunity in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.73 Real World Evidence Market Opportunity in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.74 Real World Evidence Market Opportunity in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.75 Real World Evidence Market Opportunity in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.76 Real World Evidence Market Opportunity in MENA, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.77 Real World Evidence Market Opportunity in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.78 Overall Real World Evidence Market Opportunity, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.79 Survey Analysis: Distribution by Type of Organization
Table 19.80 Survey Analysis: Distribution by Location of Organization
Table 19.81 Survey Analysis: Distribution by Seniority Level
Table 19.82 Survey Analysis: Distribution by Types of Services Offered
Table 19.83 Survey Analysis: Distribution by Real World Data Sources
Table 19.84 Survey Analysis: Distribution by Applications of Real World Evidence Generation
Table 19.85 Survey Analysis: Distribution by Key Challenges
Table 19.86 Survey Analysis: Distribution by Extent of Outsourcing
Table 19.87 Survey Analysis: Distribution by Average Budget Allocated by Big Pharmaceutical Companies

List Of Companies

The following companies / organizations have been mentioned in this report.

  1. 2 GL Outsourcing
  2. 23andMe
  3. 8KMiles
  4. AbbVie
  5. Acceliant
  6. Accenture
  7. Accsight
  8. Adarna Health Data
  9. Adelphi Real World
  10. Advera Health Analytics
  11. Aetion
  12. AG Mednet
  13. Aixial
  14. Akeso Medical Holdings
  15. Allergan
  16. Allscripts
  17. Alpha MD
  18. AMA Innovation Lab
  19. Amazon Web Services
  20. American College of Cardiology
  21. Amgen
  22. Ana Health
  23. Anne Arundel Medical Center
  24. Anthem
  25. Arcana Institute
  26. Arena International Events
  27. Arm
  28. AstraZeneca
  29. ASUS Life
  30. ATAI Life Sciences
  31. Atrium Health
  32. Axonal-Biostatem
  33. Axtria
  34. Bayer
  35. BC Platforms
  36. Beth Israel Deaconess Medical Center
  37. Bio Valley
  38. Biocruces Bizkaia Health Reseach Institute
  39. Bioserv
  40. Boehringer Ingelheim
  41. Boston Health Economics 
  42. Boston Scientific Corporation
  43. Boston University
  44. Bridge Medical
  45. Brigham and Women's Hospital
  46. Bristol-Myers Squibb
  47. Cambridge Healthtech Institute
  48. Cambridgeshire Community Reuse and Recycling Network
  49. Carevive
  50. CB Insights
  51. CBI Events
  52. Cegedim Strategic Data (CSD)
  53. Celeri Health
  54. Centers for Disease Control and Prevention
  55. Centre Hospitalier Intercommunal Robert Ballanger
  56. Certara
  57. CHA Medical Group
  58. Chinese Biopharmaceutical Association 
  59. Ciox Health
  60. Cisiv
  61. CitiusTech
  62. CK Aspire
  63. Clarivate Analytics
  64. Cleveland Clinic
  65. Clinakos
  66. ClinaMetrics
  67. Clinerion
  68. Clinical Practice Research Datalink
  69. Clinical Trial EndPoint
  70. Clinigen Group
  71. Cloudera
  72. CloudMoyo
  73. Cluell
  74. Cogentia Healthcare Consulting
  75. Cognizant 
  76. conferenceseries.com
  77. ConvergeHEALTH by Deloitte
  78. Corrona
  79. Cota Healthcare
  80. Covance
  81. Crossix Solutions
  82. CSS
  83. CTI Clinical Trial and Consulting Services
  84. Custodix
  85. Cytel
  86. D Cube Analytics
  87. Daiichi Sankyo
  88. Dartmouth-Hitchcock Medical Center
  89. Data2Life
  90. Databricks
  91. Datavant
  92. DCC 
  93. Decision Driver Analytics
  94. Decision Resources Group
  95. Dendrite Clinical Systems
  96. DHIS2
  97. DIGIPHARM
  98. Digital Health Labs
  99. Diplomat
  100. docdok.health
  101. Dresden International University
  102. Drug Information Association
  103. Drug Intelligence
  104. Duke Company
  105. Duke University
  106. Duke-Margolis Center for Health Policy
  107. Duke-NUS Medical School
  108. DuPage Medical Group
  109. eClinical Forum
  110. Econcare
  111. Eli Lilly
  112. Elligo Health Research
  113. Ephicacy
  114. EPID Research
  115. EPM Group
  116. ERN GUARD-Heart
  117. Ernst & Young Global
  118. ESiOR
  119. EUCROF
  120. European Medicines Agency
  121. European Society of Cardiology
  122. EVERSANA
  123. Evex Medical
  124. Evidence Based Solutions
  125. Evidera
  126. Evidilya
  127. Excelra
  128. ExL Events 
  129. eyeforpharma
  130. Financial Times
  131. Flatiron Health
  132. Flex
  133. Food and Drug Law Institute 
  134. Friends of Cancer Research
  135. Fuzzy Logix
  136. Gate2Biotech
  137. Genentech
  138. Genospace
  139. GlaxoSmithKline
  140. GNS Healthcare
  141. Graticule
  142. GSK
  143. Hanson Wade
  144. Happy Life Technology
  145. Harvard Medical School
  146. Harvard Pilgrim Health Care Institute 
  147. Healiant
  148. Healint
  149. Health Canada
  150. Health IQ
  151. Health Solutions
  152. Health Technology Assessment international
  153. Healthagen
  154. Healthcare Information and Management Systems Society
  155. HealthCore
  156. Healthing Research
  157. HealThink
  158. HealthVerity
  159. Hospital Clinic of Barcelona
  160. Hospital Costa del Sol
  161. Hospital de Basurto
  162. Hospital del Mar
  163. Hospital Galdakao-Usansolo
  164. Hospital São Domingos
  165. Hospital Universitario Araba
  166. Hospital Universitario Donostia
  167. Houston Methodist Hospital 
  168. Huron
  169. IBC Asia
  170. IBM Watson Health (IBM)
  171. iClusion
  172. ICON
  173. Idorsia
  174. IEEE
  175. Ignite Data
  176. IMI GetReal
  177. Imperial College Health Partners
  178. Indegene
  179. Infosys
  180. Ingress Health
  181. Innovation Enterprise
  182. Inovalon
  183. Insight Pharma Services
  184. Institute of Statistical, Social and Economic Research
  185. Instituto de Salud Carlos III
  186. Intel
  187. Inteliquet
  188. International Business Machines
  189. International Center for Entrepreneurial Development
  190. International Coalition of Medicines Regulatory Authorities
  191. International Society for Pharmacoeconomics and Outcomes Research
  192. International Society for Pharmacoeconomics and Outcomes Research
  193. IntrinsiQ Specialty Solutions
  194. IQVIA
  195. Istituto Auxologico Italiano
  196. iTakeControl
  197. iwantGreatCare
  198. Janssen
  199. JDRF
  200. Johaus Global
  201. Johns Hopkins University
  202. Kaiku Health
  203. Kaiser Permanente
  204. Kantar Health
  205. Keyrus Biopharma
  206. KNect365
  207. Koneksa Health
  208. Kx Systems
  209. LINK Medical Research
  210. LMC Manna Research
  211. London School of Economics and Political Science
  212. LynxCare
  213. M2Gen
  214. M2S
  215. MA Provider
  216. MakroCare
  217. MAP BioPharma
  218. MAP Group (Acquired by ICON)
  219. marcus evans
  220. MarketsandMarkets
  221. MarkLogic
  222. MarksMan Healthcare Communications
  223. Massachusetts General Hospital
  224. Massachusetts Institute of Technology  
  225. MaxisIT
  226. Mayo Clinic
  227. McDougall Scientific
  228. McKesson
  229. MDC Partners
  230. MeaningCloud
  231. Medaffcon
  232. Med-e Share
  233. MedEngine
  234. Medialis
  235. Medical College of Wisconsin
  236. Medical Wisdom Consulting Group
  237. Medidata
  238. Medimix International (Acquired by Evidera)
  239. MeDiNova Research
  240. Medlior Health Outcomes Research 
  241. Medpace
  242. MedPass International 
  243. MedSoft
  244. Medstreaming
  245. Medtronic
  246. Medway NHS Foundation Trust
  247. Meiji Pharmaceutical University 
  248. Merck
  249. Mercy Technology Services
  250. Metaforms
  251. Methodist Health System
  252. Model Answers 
  253. MolecularMD (Acquired by ICON)
  254. MyOwnMed
  255. National Association of Managed Care Physicians 
  256. National Cancer Institute
  257. National Health Service Trust
  258. National Institute for Health and Care Excellence
  259. National Institutes of Health
  260. National Research Center for Preventive Medicine
  261. Neox
  262. Noona
  263. Nordic HTA
  264. Northern Alberta Clinical Trials and Research Centre
  265. NorthWest EHealth
  266. Novartis
  267. Novo Nordisk
  268. Numerus
  269. NYU Langone Health
  270. O4 Research
  271. Observational & Pragmatic Research Institute
  272. Odysseus Data Services
  273. OKRA Technologies
  274. OM1
  275. Omega CRO
  276. Oncocare Health Incorporated
  277. OncoStats
  278. OPEN Health
  279. Optra Systems
  280. OptumInsight
  281. Opyl
  282. Oracle
  283. OrbitalRX
  284. Oriola
  285. ORPHA Strategy Consulting
  286. Orphazyme
  287. OXON Epidemiology
  288. Palantir
  289. PAREXEL
  290. Patient iP
  291. PatientsLikeMe
  292. PatientSource
  293. PCORnet
  294. Pentavere
  295. Peripharm
  296. PerkinElmer
  297. Pfizer
  298. pH Associates
  299. Pharma Industry Finland
  300. Pharma Intelligence
  301. Pharmaceuticals and Medical Devices Agency (PMDA)
  302. PharmaLand Consulting Group
  303. Pharmerit International
  304. PHARMO Institute for Drug Outcomes Research
  305. phUSE
  306. Pitié-Salpêtrière University Hospital
  307. Point-of-Care Partners
  308. PotentiaMED
  309. PRA Health Sciences
  310. Precision Digital Health
  311. Premier
  312. Provisio
  313. Public Health England
  314. Qlik
  315. Quantify Research
  316. Quantzig
  317. Raven Biosciences
  318. Real Consulting Data
  319. REAL Europe
  320. Real Life Sciences
  321. RealHealthData
  322. Reuters Events
  323. Roam
  324. Roche
  325. RTI Health Solutions
  326. RWE Genesys
  327. RxAnte
  328. S3 Connected Health
  329. S4 Research
  330. Saama Technologies
  331. Sanofi
  332. Sino-American Pharmaceutical Professionals Association -Greater Philadelphia 
  333. Sapungo
  334. SAS
  335. Savana
  336. Sciformix
  337. Self Care Catalysts
  338. Semicrol
  339. Sentry Data Systems
  340. SerenaGroup
  341. SHYFT Analytics
  342. SmartAnalyst
  343. SMi Group
  344. Society for Clinical Research Sites
  345. Southwood Research
  346. Spanish Data Protection Agency
  347. SPRIM Advanced Life Sciences
  348. SQN Clinical 
  349. St George's University Hospitals NHS Foundation Trust
  350. Stanford University
  351. StatFinn
  352. Strategy Institute
  353. SVMPharma
  354. Syapse
  355. Symphony Health Solutions
  356. Syneos Health
  357. Synergus
  358. Syntel
  359. Takeda Pharmaceuticals
  360. Talking Medicines
  361. Talosix
  362. Target RWE
  363. TCD Outcomes Research
  364. TCD Research
  365. TCR Solutions
  366. Techtrials International
  367. Tempus
  368. Terrapinn Holdings
  369. TFS
  370. Accelerated Cure Project
  371. The Association of the Pharmaceutical Industry in Norway
  372. European Epidemiological Forum
  373. The Evidence Base
  374. The Health and Medicine Division
  375. The National Patient-Centered Clinical Research Network 
  376. The Wound Treatment Center
  377. Thomas Jefferson University
  378. TriNetX
  379. Trinity Industries
  380. T-Systems
  381. TTi Healthcare and Economics
  382. Tufts Center for the Study of Drug Development
  383. Turacoz Healthcare Solutions
  384. U.S. Department of Veterans Affairs
  385. UCSF-Stanford Center of Excellence in Regulatory Science and Innovation
  386. uMotif
  387. United BioSource (UBC)
  388. United States Food and Drug Administration
  389. University College London
  390. University Hospitals
  391. University Hospital of the Nuestra Senora de Candelaria
  392. University of Amsterdam
  393. University of California
  394. University of Cambridge
  395. University of Colorado
  396. University of Ghana
  397. University of Michigan
  398. University of Minnesota
  399. University of North Carolina
  400. University of Pennsylvania
  401. University of Pittsburgh
  402. University of Southern California
  403. University of Wisconsin
  404. VA Office of Research and Development
  405. Validic
  406. Vecna
  407. Verana Health
  408. Verantos
  409. Verily Life Sciences
  410. Vestrum Health
  411. Vitaccess
  412. Vital Statistics Consulting
  413. Vonlanthen Group
  414. Wake Forest University Health Sciences
  415. Wellframe
  416. West Monroe Partners
  417. William Beaumont Hospital
  418. Wipro
  419. World Congress
  420. Worldwide Clinical Trials
  421. Xcenda
  422. xCures
  423. Yale University
  424. Zeblok
  425. ZEINCRO
  426. Zem Solutions
  427. Zephyr Health
  428. ZM Company
  429. ZS Company

Segmentation

The USD 4.5 billion (by 2030) financial opportunity within the real world evidence market has been analyzed across the following segments:

  • Type of Application 
    • Early Stage Research 
    • Clinical Development
    • Regulatory Approval, Pricing / Reimbursement
    • Post-Approval Studies
  • Types of Real World Data Sources
    • Medical Claims
    • Clinical Trials
    • Clinical Setting
    • Patient Powered
    • Other Data Sources
  • Therapeutic Area
    • Autoimmune Disorders 
    • Cardiovascular Disorders
    • Infectious Diseases
    • Metabolic Disorders
    • Neurological / Psychiatric Disorders
    • Oncological Disorders
    • Respiratory Disorders
    • Other Disorders
  • Geography
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East and North Africa
    • Rest of the World

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com